Navigation Links
PARI Pharma Presents Study Results of Sinus Delivery and Inhaled,Liposomal Ciclosporin A at European Cystic Fibrosis Conference

MUNICH, Germany, June 14, 2007 /PRNewswire/ -- PARI Pharma will present in-vivo study results for their PARI SINUS pulsating drug delivery system as well as lung deposition and pharmacokinetic data of their proprietary inhaled liposomal Ciclosporin A formulation in lung transplant patients at the European Cystic Fibrosis Conference (ECFC) in Belek, Turkey this week.

Continuing their tradition of developing highly advanced inhalation delivery platforms, PARI has created a pulsating sinus drug delivery system to target the upper respiratory tract. Study results at ECFC will focus on visual deposition results using dynamic 81mKr-gas ventilation imaging.

In a separate poster presentation, study results will be presented showing lung deposition and pharmacokinetics of inhaled Ciclosporin A given to 12 lung transplanted patients using PARI Pharma's proprietary liposomal platform technology delivered via a customized eFlow electronic nebulizer. Inhaled Ciclosporin A is a potential therapy for lung transplant patients that is hoped to improve survival rates while reducing side effects by targeting drug delivery of a Ciclosporin A formulation with eFlow so that lower doses of drug may be effective. Using a vibrating membrane, eFlow can produce aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible period of time.

About ECFC

The European Cystic Fibrosis Conference, held by the European Cystic Fibrosis Society, focuses on international advancements in the treatment of cystic fibrosis. Cystic fibrosis is an inherited chronic disease that affects the lungs and digestive systems of an estimated 70,000 children and adults worldwide. Additional information is available online at http://www.europeancfconference.org.

Abo ut PARI Pharma

PARI Pharma develops aerosol delivery devices and inhaled therapies. Based on PARI's 100-year history working with aerosols, PARI Pharma specializes in treatments for pulmonary and nasal administration optimized to advanced delivery platforms, such as eFlow.

Focusing on comprehensive inhalation therapy development, including optimized nebulizer formulations, analytics, and aerosol characterization, PARI Pharma has several clinical development programs ongoing, either partnered or proprietary. PARI Pharma, a PARI Medical Holding company, is located in Munich, Germany, with a major presence in the United States. Online at http://www.paripharma.com

CONTACT: Kirsten Ayars of Ayars & Associates, +1-805-452-7909, for PARIPharma; or Geoff Hunziker, of PARI Pharma , +1-831-372-3580

Web site: http://www.paripharma.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 2017  CVS Pharmacy is the first national retail ... oils (PHO), the primary source of artificial trans fats ... food products. The retailer now offers over 600 exclusive ... trans fats. This comes a year and a half ahead ... 2018 for processed foods to be reformulated without artificial ...
(Date:2/22/2017)... Des scanners sur smartphone destinés aux professionnels de ... , au Moyen-Orient et en Afrique  ... Clarius Mobile Health , une société de santé numérique ... Canada , a annoncé aujourd,hui qu,elle a reçu la ... Clarius C3 et L7, destinés à être utilisés par des professionnels de ...
(Date:2/22/2017)... LUND, Sweden , Feb 22, 2017 ... the mitochondrial medicine company, today announced two new research ... , PhD, and Professor Massimo Pinzani , MD, ... agreements is to further explore NeuroVive,s new drug compounds ... carcinoma (HCC). In the new collaboration ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... BrightStar Care Charleston , a ... Medical University of South Carolina (MUSC) Center on Aging’s Senior Expo on Thursday, ... on Aging is a tremendous resource in our community. We are thrilled to participate ...
(Date:2/22/2017)... ... February 22, 2017 , ... Alto-Shaam is pleased ... Series Multi-Cook Oven offers up to four ovens in one. Control temperature, fan ... for unmatched evenness in cooking. Alto-Shaam has partnered with Appliance Innovation to introduce ...
(Date:2/21/2017)... (PRWEB) , ... February 22, 2017 , ... Author Michèle ... is valuable for every household and family to know all about it for optimal ... world with the release of “ Detox, Digestive and Wellness Solutions ” (published by ...
(Date:2/21/2017)... ... 2017 , ... Hanna Boys Center http://www.hannacenter.org is ... keynote speaker at its second Professional Networking Breakfast on March 9, 2017. Marc ... strategies to create and expand opportunities for boys and young men of color ...
(Date:2/21/2017)... ... 21, 2017 , ... Individuals who have been diagnosed with ... treatment, therapy and management. Regular exercise in proper environments has been shown to ... diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic HydroWorx webinar ...
Breaking Medicine News(10 mins):